Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00554229




Registration number
NCT00554229
Ethics application status
Date submitted
2/11/2007
Date registered
6/11/2007
Date last updated
8/02/2016

Titles & IDs
Public title
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
Scientific title
A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.
Secondary ID [1] 0 0
2007-003227-20
Secondary ID [2] 0 0
D4320C00014
Universal Trial Number (UTN)
Trial acronym
ENTHUSE M1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Prostate Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Prostate

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - ZD4054
Treatment: Drugs - Placebo

Experimental: ZD4054 - ZD4054 10 mg oral tablet once daily

Placebo comparator: Placebo - Matching Placebo, oral tablets once daily


Treatment: Drugs: ZD4054
ZD4054 10 mg oral tablet once daily

Treatment: Drugs: Placebo
Matching placebo oral tablet once daily
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival
Timepoint [1] 0 0
From date of randomization until date of death, assessed up to 32 months
Secondary outcome [1] 0 0
Progression Free Survival
Timepoint [1] 0 0
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 31 months
Secondary outcome [2] 0 0
Time to Use of Opiates
Timepoint [2] 0 0
From date of randomization until use of opiates for disease-related symptoms for a duration =1 week, assessed up to 31 months
Secondary outcome [3] 0 0
Incidence of Skeletal Related Events
Timepoint [3] 0 0
From date of randomization until occurrence of a skeletal related event, assessed up to 31 months
Secondary outcome [4] 0 0
Bone Metastases Formation
Timepoint [4] 0 0
Patients were assessed every 12 weeks
Secondary outcome [5] 0 0
Health Related Quality of Life
Timepoint [5] 0 0
Patients were assessed at every visit
Secondary outcome [6] 0 0
Time to Prostate-specific Antigen (PSA) Progression
Timepoint [6] 0 0
Patients were assessed every 12 weeks
Secondary outcome [7] 0 0
Time to Pain Progression
Timepoint [7] 0 0
Patients were assessed every 12 weeks
Secondary outcome [8] 0 0
Time to Initiation of Chemotherapy
Timepoint [8] 0 0
Patients were assessed every 12 weeks
Secondary outcome [9] 0 0
Pharmacokinetic Characteristics of ZD4054
Timepoint [9] 0 0
PK samples were performed at randomisation, Week 4, Week 8 and Week 12

Eligibility
Key inclusion criteria
Patients who answer TRUE to the following criteria may be eligible to participate in this trial.

1. Confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate) that has spread to the bone (bone metastases)
2. Increasing Prostate Specific Antigen (PSA) over a one month period
3. No pain, or mild pain from prostate cancer
4. Currently receiving treatment with surgical or medical castration
Minimum age
18 Years
Maximum age
No limit
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
Patients who answer TRUE to the following may NOT eligible to participate in this trial.

1. Currently using opiates based pain killers)
2. Previous treatment with chemotherapy (paclitaxel, docetaxel, and mitoxantrone)
3. Suffering from heart failure or had a myocardial infarction within last 6 months
4. A history of epilepsy or seizures

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/11/2007
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/08/2011
Sample size
Target
Accrual to date
Final
896
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA
Recruitment hospital [1] 0 0
Research Site - Hornsby
Recruitment hospital [2] 0 0
Research Site - St Leonards
Recruitment hospital [3] 0 0
Research Site - Redcliffe
Recruitment hospital [4] 0 0
Research Site - Ashford
Recruitment hospital [5] 0 0
Research Site - Subiaco
Recruitment postcode(s) [1] 0 0
- Hornsby
Recruitment postcode(s) [2] 0 0
- St Leonards
Recruitment postcode(s) [3] 0 0
- Redcliffe
Recruitment postcode(s) [4] 0 0
- Ashford
Recruitment postcode(s) [5] 0 0
- Subiaco
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Iowa
Country [7] 0 0
United States of America
State/province [7] 0 0
Ohio
Country [8] 0 0
United States of America
State/province [8] 0 0
Pennsylvania
Country [9] 0 0
United States of America
State/province [9] 0 0
Tennessee
Country [10] 0 0
United States of America
State/province [10] 0 0
Utah
Country [11] 0 0
United States of America
State/province [11] 0 0
Vermont
Country [12] 0 0
United States of America
State/province [12] 0 0
Virginia
Country [13] 0 0
United States of America
State/province [13] 0 0
Washington
Country [14] 0 0
United States of America
State/province [14] 0 0
West Virginia
Country [15] 0 0
United States of America
State/province [15] 0 0
Wisconsin
Country [16] 0 0
Argentina
State/province [16] 0 0
Buenos Aires Province
Country [17] 0 0
Argentina
State/province [17] 0 0
Santa Fe Province
Country [18] 0 0
Austria
State/province [18] 0 0
Graz
Country [19] 0 0
Austria
State/province [19] 0 0
Wels
Country [20] 0 0
Belgium
State/province [20] 0 0
Brussels
Country [21] 0 0
Belgium
State/province [21] 0 0
Gent
Country [22] 0 0
Belgium
State/province [22] 0 0
Kortrijk
Country [23] 0 0
Belgium
State/province [23] 0 0
Leuven
Country [24] 0 0
Brazil
State/province [24] 0 0
Ceara
Country [25] 0 0
Brazil
State/province [25] 0 0
Goias
Country [26] 0 0
Brazil
State/province [26] 0 0
Minas Gerais
Country [27] 0 0
Brazil
State/province [27] 0 0
Parana
Country [28] 0 0
Brazil
State/province [28] 0 0
Rio Grande do Sul
Country [29] 0 0
Brazil
State/province [29] 0 0
Sao Paulo
Country [30] 0 0
Canada
State/province [30] 0 0
Alberta
Country [31] 0 0
Canada
State/province [31] 0 0
British Columbia
Country [32] 0 0
Canada
State/province [32] 0 0
Nova Scotia
Country [33] 0 0
Canada
State/province [33] 0 0
Ontario
Country [34] 0 0
Canada
State/province [34] 0 0
Quebec
Country [35] 0 0
China
State/province [35] 0 0
Beijing
Country [36] 0 0
China
State/province [36] 0 0
Hubei
Country [37] 0 0
China
State/province [37] 0 0
Jiangsu
Country [38] 0 0
China
State/province [38] 0 0
Shanghai
Country [39] 0 0
China
State/province [39] 0 0
Shanxi
Country [40] 0 0
Czech Republic
State/province [40] 0 0
Prague
Country [41] 0 0
Czech Republic
State/province [41] 0 0
Brno
Country [42] 0 0
Czech Republic
State/province [42] 0 0
Olomouc
Country [43] 0 0
Czech Republic
State/province [43] 0 0
Usti nad Labem
Country [44] 0 0
Denmark
State/province [44] 0 0
Aalborg
Country [45] 0 0
Denmark
State/province [45] 0 0
Aarhus
Country [46] 0 0
Denmark
State/province [46] 0 0
Herlev
Country [47] 0 0
Denmark
State/province [47] 0 0
Kobenhavn
Country [48] 0 0
Finland
State/province [48] 0 0
Joensuu
Country [49] 0 0
Finland
State/province [49] 0 0
Kajaanintie
Country [50] 0 0
Finland
State/province [50] 0 0
Tampere
Country [51] 0 0
France
State/province [51] 0 0
Montpellier
Country [52] 0 0
France
State/province [52] 0 0
Paris
Country [53] 0 0
France
State/province [53] 0 0
Poitiers Cedex
Country [54] 0 0
France
State/province [54] 0 0
Suresnes
Country [55] 0 0
France
State/province [55] 0 0
Toulouse
Country [56] 0 0
France
State/province [56] 0 0
Villejuif
Country [57] 0 0
Germany
State/province [57] 0 0
Muenchen
Country [58] 0 0
Germany
State/province [58] 0 0
Teck
Country [59] 0 0
Germany
State/province [59] 0 0
Augsburg
Country [60] 0 0
Germany
State/province [60] 0 0
Bad Gegeberg
Country [61] 0 0
Germany
State/province [61] 0 0
Berlin
Country [62] 0 0
Germany
State/province [62] 0 0
Emmendingen
Country [63] 0 0
Germany
State/province [63] 0 0
Leipzig
Country [64] 0 0
Germany
State/province [64] 0 0
Luebeck
Country [65] 0 0
Germany
State/province [65] 0 0
Mannheim
Country [66] 0 0
Germany
State/province [66] 0 0
Reutlingen
Country [67] 0 0
Hong Kong
State/province [67] 0 0
Hong Kong
Country [68] 0 0
Hong Kong
State/province [68] 0 0
Shatin
Country [69] 0 0
Hong Kong
State/province [69] 0 0
Tuen Mun
Country [70] 0 0
Hungary
State/province [70] 0 0
Budapest
Country [71] 0 0
Hungary
State/province [71] 0 0
Debrecen
Country [72] 0 0
Hungary
State/province [72] 0 0
Miskolc
Country [73] 0 0
Hungary
State/province [73] 0 0
Nyiregyhaza
Country [74] 0 0
Hungary
State/province [74] 0 0
Szeged
Country [75] 0 0
India
State/province [75] 0 0
Delhi
Country [76] 0 0
India
State/province [76] 0 0
Kerala
Country [77] 0 0
India
State/province [77] 0 0
Madhya Pradesh
Country [78] 0 0
India
State/province [78] 0 0
Maharashtra
Country [79] 0 0
India
State/province [79] 0 0
Punjab
Country [80] 0 0
India
State/province [80] 0 0
Rajasthan
Country [81] 0 0
India
State/province [81] 0 0
West Bengal
Country [82] 0 0
India
State/province [82] 0 0
Gujarat
Country [83] 0 0
India
State/province [83] 0 0
New Delhi
Country [84] 0 0
Italy
State/province [84] 0 0
Milan
Country [85] 0 0
Italy
State/province [85] 0 0
Rome
Country [86] 0 0
Japan
State/province [86] 0 0
Chiba
Country [87] 0 0
Japan
State/province [87] 0 0
Ehime
Country [88] 0 0
Japan
State/province [88] 0 0
Fukuoka
Country [89] 0 0
Japan
State/province [89] 0 0
Gunma
Country [90] 0 0
Japan
State/province [90] 0 0
Hiroshima
Country [91] 0 0
Japan
State/province [91] 0 0
Hokkaido
Country [92] 0 0
Japan
State/province [92] 0 0
Hyogo
Country [93] 0 0
Japan
State/province [93] 0 0
Ibaraki
Country [94] 0 0
Japan
State/province [94] 0 0
Kagawa
Country [95] 0 0
Japan
State/province [95] 0 0
Kanagawa
Country [96] 0 0
Japan
State/province [96] 0 0
Kyoto
Country [97] 0 0
Japan
State/province [97] 0 0
Miyagi
Country [98] 0 0
Japan
State/province [98] 0 0
Oita
Country [99] 0 0
Japan
State/province [99] 0 0
Osaka
Country [100] 0 0
Japan
State/province [100] 0 0
Saitama
Country [101] 0 0
Japan
State/province [101] 0 0
Shizuoka
Country [102] 0 0
Japan
State/province [102] 0 0
Tokyo
Country [103] 0 0
Japan
State/province [103] 0 0
Nagasaki
Country [104] 0 0
Korea, Republic of
State/province [104] 0 0
Chungbuk
Country [105] 0 0
Korea, Republic of
State/province [105] 0 0
Gyeonggi-do
Country [106] 0 0
Korea, Republic of
State/province [106] 0 0
Pusan
Country [107] 0 0
Korea, Republic of
State/province [107] 0 0
Seoul
Country [108] 0 0
Mexico
State/province [108] 0 0
Estado de Mexico
Country [109] 0 0
Mexico
State/province [109] 0 0
Distrito Federal Ciudad
Country [110] 0 0
Mexico
State/province [110] 0 0
Mexico City
Country [111] 0 0
Netherlands
State/province [111] 0 0
Amsterdam
Country [112] 0 0
Netherlands
State/province [112] 0 0
Eindhoven
Country [113] 0 0
Netherlands
State/province [113] 0 0
Groningen
Country [114] 0 0
Netherlands
State/province [114] 0 0
Nijmegen
Country [115] 0 0
Poland
State/province [115] 0 0
Bialystok
Country [116] 0 0
Poland
State/province [116] 0 0
Koscierzyna
Country [117] 0 0
Poland
State/province [117] 0 0
Krakow
Country [118] 0 0
Poland
State/province [118] 0 0
Rzeszow
Country [119] 0 0
Poland
State/province [119] 0 0
Warszawa
Country [120] 0 0
Poland
State/province [120] 0 0
Wroclaw
Country [121] 0 0
Portugal
State/province [121] 0 0
Coimbra
Country [122] 0 0
Portugal
State/province [122] 0 0
Lisboa
Country [123] 0 0
Portugal
State/province [123] 0 0
Porto
Country [124] 0 0
Russian Federation
State/province [124] 0 0
Belgorodskaya region
Country [125] 0 0
Russian Federation
State/province [125] 0 0
Barnaul
Country [126] 0 0
Russian Federation
State/province [126] 0 0
Izhevsk
Country [127] 0 0
Russian Federation
State/province [127] 0 0
Kursk
Country [128] 0 0
Russian Federation
State/province [128] 0 0
Moscow
Country [129] 0 0
Russian Federation
State/province [129] 0 0
Sochi
Country [130] 0 0
Russian Federation
State/province [130] 0 0
St. Petersgurg
Country [131] 0 0
Russian Federation
State/province [131] 0 0
Voronezh
Country [132] 0 0
Serbia
State/province [132] 0 0
Belgrade
Country [133] 0 0
Serbia
State/province [133] 0 0
Nis
Country [134] 0 0
Serbia
State/province [134] 0 0
Novi Sad
Country [135] 0 0
Singapore
State/province [135] 0 0
Singapore
Country [136] 0 0
South Africa
State/province [136] 0 0
Cape Town
Country [137] 0 0
South Africa
State/province [137] 0 0
Bloemfontein
Country [138] 0 0
South Africa
State/province [138] 0 0
Pietermaritzburg
Country [139] 0 0
South Africa
State/province [139] 0 0
Port Elizabeth
Country [140] 0 0
Sweden
State/province [140] 0 0
Goteborg
Country [141] 0 0
Sweden
State/province [141] 0 0
Gothenburg
Country [142] 0 0
Sweden
State/province [142] 0 0
Stockholm
Country [143] 0 0
Switzerland
State/province [143] 0 0
Basel
Country [144] 0 0
Switzerland
State/province [144] 0 0
Bern
Country [145] 0 0
Switzerland
State/province [145] 0 0
Locarno
Country [146] 0 0
Switzerland
State/province [146] 0 0
Sursee
Country [147] 0 0
Taiwan
State/province [147] 0 0
Kaohsiung
Country [148] 0 0
Taiwan
State/province [148] 0 0
Taipei
Country [149] 0 0
Taiwan
State/province [149] 0 0
Taoyuan
Country [150] 0 0
United Kingdom
State/province [150] 0 0
Berkshire
Country [151] 0 0
United Kingdom
State/province [151] 0 0
Cambridgeshire
Country [152] 0 0
United Kingdom
State/province [152] 0 0
Kent
Country [153] 0 0
United Kingdom
State/province [153] 0 0
Yorkshire
Country [154] 0 0
United Kingdom
State/province [154] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Enthuse M1 is a large phase III clinical trial studying the safety and efficacy of ZD4054 (Zibotentan) in patients with hormone resistant prostate cancer and bone metastases.

* This clinical trial will test if the Endothelin A Receptor Antagonist ZD4054 (Zibotentan) can improve survival compared with placebo.
* ZD4054(Zibotentan) is a new type of agent, which is thought to slow tumour growth and spread by blocking Endothelin A receptor activity. This trial will look at the effects of ZD4054 (Zibotentan) in hormone resistant prostate cancer patients with bone metastases.
* All patients participating in this clinical trial will receive existing standard prostate cancer treatments in addition to trial therapy.
* Half the patients will receive ZD4054 (Zibotentan), and half the patients will receive placebo in addition to standard prostate cancer therapy. By participating in this trial there is a 50% chance that patients will receive an agent that may slow the progression of the tumour.
* No patients will be deprived of standard prostate cancer therapy.
Trial website
https://clinicaltrials.gov/study/NCT00554229
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Martin Gleave, MD, FRCSC, FACS
Address 0 0
The Prostate Centre at Vancouver General Hospital
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00554229